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PREAMBLE
Thoracic endovascular aortic repair (TEVAR) is an emerging treat-
ment modality, which has been rapidly embraced by clinicians
treating thoracic aortic disease [1–4]. Fundamentally, it is a far
less invasive approach than open surgery and its availability and
relative ease of application has changed and extended manage-
ment options in thoracic aortic disease, including in those
patients deemed unﬁt or unsuitable for open surgery. In the
operating room, this requires considerable perceptual, cognitive
and psychomotor demands on the operators.
The dramatic expansion of TEVAR activity has necessarily
prompted a requirement to systematically consider the indica-
tions, appropriateness, limitations and delivery of this treatment,
which has been adopted by many specialties including cardiolo-
gists, cardiovascular surgeons, radiologists and vascular surgeons
[5]. Our task has been to generate a multidisciplinary position
statement that supports and advises all clinicians utilizing this
technological advance. This document focuses on the main
diagnoses—thoracic aortic aneurysm (TAA), thoracic aortic dissec-
tion (TAD) of the descending aorta (type B according to the
Stanford classiﬁcation) and thoracic aortic injury (TAI)—indications
and applicability of TEVAR and includes information regarding its
limitations and complications. It acts as a position statement for
both societies that reﬂects current understanding of thoracic
aortic endovascular therapy.
†This joint statement, which represents the views of the EACTS and the ESC,
was arrived at after careful consideration of the available evidence at the time
it was written. Health professionals are encouraged to take the joint state-
ment fully into account when exercising their clinical judgement. The joint
statement does not, however, override the individual responsibility of health
professionals to make appropriate decisions in the circumstances of the indi-
vidual patients, in consultation with that patient, and where appropriate and
necessary the patient's guardian or carer. It is also the health professional's re-
sponsibility to verify the rules and regulations applicable to drugs and devices
at the time of prescription.
© The Author 2012. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery and the European Society of
Cardiology. All rights reserved.
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RECOMMENDATIONS FOR THE DEVELOPMENT
OF A TEVAR PROGRAMME
Evaluation of symptoms and patient status
Symptoms in patients with TAA and chronic dissection are rare
and non-speciﬁc [6, 7]. New onset of hoarseness or dysphagia
may suggest a developing aneurysm in the distal aortic arch and
proximal descending aorta. Most asymptomatic cases are discov-
ered incidentally, while symptomatic patients have usually
developed complications. Even in patients with acute aortic
syndromes, chest pain, back pain and signs of malperfusion are
often misinterpreted due to lack of awareness. In cases of clinical
suspicion, a computed tomography (CT)-angiography is the diag-
nostic modality of ﬁrst choice.
Multidisciplinary consultation
Patient selection should be performed on an individual basis accord-
ing to anatomy, pathology, comorbidity and anticipated durability of
any repair, using a multidisciplinary approach, ideally in an aortic
centre. This concept offers the widest available opinion, an appropri-
ate range of technical options and adequate infrastructure for endo-
vascular therapy of thoracic aortic disease. The involvement of
different specialties allows combining the best experience and
expertise in medical, interventional and surgical therapy for tailoring
an optimal treatment strategy for the individual patient.
Preoperative imaging
CT angiography (CTA) is the method of choice for diagnosis and
planning treatment [8]. Magnetic resonance imaging (MRI) is not
widely used in the acute setting, but may be useful in chronic
disease and during follow-up [9]. Conventional angiography is no
longer recommended as a routine diagnostic procedure. Positron
emission tomography in combination with CTA may be used as
an adjunct in speciﬁc situations (detection of signs of inﬂamma-
tion) but is not recommended for routine use [10, 11].
Intraprocedural imaging
High-quality imaging and appropriate facilities for open surgery
during the endovascular procedure are of the utmost importance.
Purpose-built, hybrid operating and imaging suites appear to be
the optimal solution [12]. Transoesophageal echocardiography
(TEE) is recommended as an adjunctive intraoperative imaging
technique in complex aortic pathologies such as aortic dissection
[13–15]. Intravascular ultrasound and phased-array intracardiac
ultrasound could be useful as well in cases of dissection [16, 17].
Postprocedural imaging
CTA prior to discharge is advised to delineate complications un-
detected during the initial endovascular procedure and to form
a reference for follow-up studies. To avoid radiation MRI may be
more widely used in the future [8], but it lacks the visualization
of metallic stent struts and is not compatible with stainless steel
endografts [18].
Risk evaluation
To date, no TEVAR-speciﬁc risk stratiﬁcation tool is available.
Clearly, an individual risk stratiﬁcation tool is required to predict
endovascular outcomes and it will be the task of such working
groups to establish a suitable tool in the near future. Until
such risk stratiﬁcation tools are available, individual patient’s
decisions will be made on the traditional basis of risk–beneﬁt
analysis [19].
Adjunctive diagnostic modalities
It is recommended that a transthoracic echocardiogram be
performed as part of the diagnostic work-up in the elective
setting in order to exclude valvular and structural heart
disease. Further imaging should include a duplex ultrasound of
the supraaortic vessels. A stress test to exclude coronary artery
disease is not necessary in asymptomatic patients [20, 21].
Cardiac catheterization is suggested in patients with proven
signs and symptoms of ischaemia or suspicion of coronary
artery disease.
Planning of TEVAR—TAA
A sufﬁcient proximal and distal landing zone of at least 2 cm is
necessary for the safe deployment and durable ﬁxation of
TEVAR [22, 23]. If landing zones are shorter or signiﬁcantly
angulated, prior transposition or bypass surgery/re-routing of
the involved aortic branch may be considered. Evaluation of
access vessels (sizing, calciﬁcation, tortuosity) is of major im-
portance. An access vessel of at least 8 mm in diameter is ne-
cessary for a standard 24 French delivery device. Alternative
access sites are the iliac arteries, the infrarenal aorta or even
the ascending aorta.
Planning of TEVAR—type B TAD
Planning of TEVAR includes clinical examination, laboratory tests
and imaging to classify the type of dissection (classical dissection,
intramural haematoma (IMH), penetrating atherosclerotic ulcer,
traumatic dissection), its duration and potential complications.
Localization of all tears, with emphasis on identifying the
primary entry tear, is important. The next step is to deﬁne the
extension of dissection and possible static, dynamic or complex
involvement of supraaortic, visceral and pelvic vessels resulting
in malperfusion [8]. Perfusion of side branch vessels through the
false lumen does not automatically exclude patients from TEVAR,
as a distal communication is often present or the visceral vessel
may receive a contribution from both lumina.
INDICATIONS AND CONTRAINDICATIONS FOR
TEVAR
TEVAR for TAA
In asymptomatic TAA patients TEVAR is indicated (by consensus)
when the maximum diameter of the aneurysm exceeds 5.5 cm
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or if rapid expansion (>5 mm in 6 months) occurs [24, 25]. In
certain morphologic situations which are considered prone to
rupture, e.g. saccular aneurysms, TEVAR may be justiﬁed at a
diameter of less the above referenced 5.5 cm. Comorbidities and
age of the patient have to be considered [26], and it may be ap-
propriate to set a larger aortic diameter threshold in patients
with increased operative risk.
TEVAR for type B aortic dissection
TEVAR is the treatment modality of choice in complicated acute
type B aortic dissections [3, 27–29]. The term ‘complicated’
means persisting or recurrent pain, uncontrolled hypertension
despite full medication, early aortic expansion, malperfusion and
signs of rupture (haematothorax, increasing periaortic and medi-
astinal haematoma) [28]. Further subgroups beneﬁting from im-
mediate TEVAR are being deﬁned. In an uncomplicated type B
dissection, a primary conservative approach with close surveil-
lance seems to be justiﬁed until complications arise [30]. The
treatment of aneurysms on the basis of chronic type B dissec-
tions should be discussed in a multidisciplinary team approach,
considering TEVAR versus open surgery [31].
In cases of penetrating aortic ulcer, treatment may be recom-
mended, when patients are symptomatic, or the ulcer demon-
strates expansion and IMH [32]. In patients with IMH, intimal
lesions/laceration can often be found in the inner curvature of
the aortic arch by careful CTA analysis. This may be an aim for
stent-graft implantation in patients with a progressive/compli-
cated IMH [32].
TEVAR for traumatic aortic injury
Immediate endovascular treatment is indicated in patients with
complete transsection of the aortic wall and free bleeding into
the mediastinum or pseudocoarctation syndrome, whereas
delayed treatment can be suggested when limited disruption of
the aorta is present but media and adventitia are intact [33–35].
Connective tissue disease
TEVAR is not recommended in patients with connective tissue
disease except as a bail-out procedure or bridge to deﬁnitive open
surgical therapy, or as a procedure following prior aortic repair
when both landing zones lie within previously sited prosthetic grafts
(e.g. intercostal patch aneurysm after Marfan’s TAA repair) [36, 37].
ENDOLEAKS
Deﬁnition of endoleak after TEVAR for TAA
Type I (proximal and/or distal reperfusion of the aneurysmal sac)
and type III endoleaks (endograft/endograft disconnection leaks)
are regarded as treatment failures and warrant further treatment
to prevent the continuing risk of rupture [38]. Type II endoleaks
(retrograde perfusion via branch vessels) are managed primarily
conservatively by a ‘wait and watch’ strategy to detect aneurys-
mal expansion, except for supraaortic arteries. In these patients
coil embolization, plug occlusion or surgical ligation should be
performed during or early after the TEVAR procedure. Type IV
(endograft porosity) and type V (endotension) endoleaks are his-
torical phenomena and are no longer observed with more
recent technology [39].
Deﬁnition of endoleak after TEVAR for TAD
The only important types of endoleaks in TAD are type Ia (ante-
grade perfusion of the false lumen) and type II (perfusion of the
false lumen via the overstented left subclavian artery). Retrograde
ﬂow from distal entry tears must not be considered as endoleaks.
DEFINITION OF TREATMENT SUCCESS
TAA
Procedural ‘technical’ success is achieved when the endograft is
deployed accurately and the aneurysm is excluded from the cir-
culation (i.e. absence of type I or III endoleak). Evaluation of clin-
ical success requires follow-up examinations of the patient
demonstrating complete thrombosis and shrinkage of the aneur-
ysm sac, and in the absence of complications.
TAD
Procedural ‘technical’ success is deﬁned as closure of the primary
entry tear (i.e. absence of type Ia endoleak) and induction of false
lumen thrombosis. The aim of endovascular treatment is to over-
come or resolve complications of aortic dissection including mal-
perfusion, imminent rupture and bleeding. This does not imply
complete immediate thrombosis of the false lumen, as further
thrombosis and remodelling processes are a matter of time.
CURRENT TECHNIQUES FOR TAAS AND TADS
Available endovascular systems
It is beyond the scope of this statement to address all manufac-
turers as well as their advantages and drawbacks. The aim of this
section is to brieﬂy discuss the different concepts regarding
design and mode of deployment. Regarding design, devices with
or without proximal uncovered struts are available. The aim of
proximal uncovered struts is to enhance proximal ﬁxation of the
prosthesis, and ensure adequate alignment of the endograft.
However, adverse events potentially associated with bare stents
including retrograde type A dissection have been reported [40,
41]. Whether these observations are causal or not remains un-
deﬁned. In terms of deployment, there is a choice between
devices with and without a tip-capture system [42, 43]. It would
appear that the availability of a tip capture may increase safety,
as blood pressure or anatomy-dependent migration or displace-
ment of the prosthesis during deployment is reduced. A tip-
capture system is recommended in patients, where proximal
stent-graft deployment is needed (cranial ascending aorta, arch).
Speciﬁcs of TEVAR for TAA
Detailed attention has to be paid to the length of the landing
zone, sufﬁcient overlapping if more than one prosthesis is being
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used, as well as angulation in the aorta and iliac arteries. The stent-
graft diameter should exceed the diameter of the landing zones
by at least 10–15% of the reference aortic diameter. Anatomic
constraints in the infrarenal aorta or the thoracoabdominal transi-
tion with excessive tortuosity may lead to a loss of pushability and
may preclude advancement of the prosthesis into the area of
interest. These difﬁcult situations may be overcome using, in add-
ition to a superstiff guidewire, a second protected stiff buddy wire
or a pull-through procedure via the brachial artery.
Speciﬁcs of TEVAR for TAD
The focus is the occlusion of the primary entry tear. The size of
the selected stent graft should be based on the diameter of the
aorta proximal to the dissected segment, applying almost no
oversizing. The technical challenge, especially in complicated
type B dissections, may be to cannulate the narrowed, some-
times collapsed true lumen. To assure access to the true lumen,
TEE may often be necessary [44]. Procedure-related difﬁculties
may be overcome by an antegrade approach via the brachial
artery with the guidewire being snared in the aorta. After de-
ployment, ballooning is not recommended, even if the stent
graft is not fully expanded, because of the self-expanding nature
of the stent and the time required for the remodelling process
of the aorta. Retrograde dissection and rupture of the dissection
membrane has been reported due to ballooning.
INTRAPROCEDURAL MONITORING
AND BLOOD PRESSURE CONTROL
Invasive blood pressure monitoring is required on a routine
basis. Cardiovascular anaesthesiologists trained in endovascular
procedures are desirable. Pharmacological lowering of blood
pressure <80 mmHg systolic during stent-graft deployment may
be sufﬁcient in many cases to avoid displacement of the device.
If further blood pressure lowering is required in proximal aortic
procedures, then rapid pacing is the method of choice [45].
VASCULAR ACCESS
Surgical cut-down is traditionally regarded as the safest way to
fully control access vessels. Percutaneous approaches are increas-
ingly used with a wide variety of techniques. At present, the
diameter and calciﬁcation of the vessel represent major limita-
tions of these devices [46]. Further reduction in the proﬁle of
stent-graft delivery device will expand the indication for percu-
taneous approaches.
COMBINED PROCEDURES
Combined surgical and endovascular techniques—so-called
hybrid procedures—have become popularized during the last
decade. Staged conventional surgical repair is associated with
signiﬁcant morbidity and mortality, due to the summation of
possible complications between ﬁrst operation, waiting period
and second surgical intervention [47].
In principle, two different approaches to extensive disease of
the aortic arch and proximal descending aorta were developed:
First, the ‘frozen elephant trunk’ technique involves conventional
surgical repair of the ascending aorta and the aortic arch com-
bined with open antegrade stent grafting of the descending
aorta in the period of circulatory arrest [48–50]. Second, re-
routing of supraaortic branches by transposition or bypass
enables endovascular treatment of the arch and proximal des-
cending aorta without need for cardiopulmonary bypass and
hypothermic circulatory arrest [23, 51]. Visceral and renal trans-
positions cannot be recommended as standard procedures for
thoraco-abdominal aneurysms as the early results of these pro-
cedures have revealed high mortality rates [52]. Clearly, further
larger series need to be awaited.
TECHNIQUES FOR NON-SURGICAL SIDE
BRANCH ACCESS
Aortic pathologies involving major side branches are a complex
challenge for endovascular repair. Implantation of a stent-graft
may result in critical ischaemia and organ dysfunction. Recently,
there has been increasing interest in the development of cath-
eter-based non-surgical techniques to address this issue.
Approaches include: (1) development of dedicated stent-graft
prostheses with fenestrations or branches for direct side branch
access, and (2) modiﬁcation of readily available interventional
techniques to establish extra-anatomic side branch perfusion (e.
g. ‘Chimney’, ‘Sandwich’ technique etc.). All these techniques are
still investigational as sufﬁcient follow-up is not yet available;
such procedures are not endorsed and should be limited to clin-
ical trials in centres of excellence or with a particular interest
until broader knowledge supports the technique [53].
PROCEDURE-RELATED COMPLICATIONS
Any vascular injury or vessel-associated injury (thrombosis,
bleeding, retrograde type A dissection, stroke) during TEVAR and
within 24 h, as well as cardiac complications (perforation of a
superstiff guidewire, myocardial injury of any kind) should be
reported as procedure-related [54].
STENT GRAFT RELATED COMPLICATIONS
The most signiﬁcant complication is retrograde type A dissection
[40, 41]. Associated factors may include radial force of uncovered
struts, diagnosis of TAD, extensive oversizing and ballooning.
Erosion of the oesophagus or the left main bronchus is an ex-
tremely rare complication and potentially more related to the
underlying disease than to the stent graft [55, 56]. Finally, in TAD,
membrane rupture at the distal end of the stent graft may occur.
This rare event is likely to be related rather to the underlying
disease, than to the size of the stent graft itself.
OUTCOME PARAMETERS
TEVAR for TAA
The main outcome parameters are survival and aortic-related
survival [22, 57]. Other clinically signiﬁcant outcome parameters
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would include rate of persisting or newly developing endoleak-
age, freedom from reintervention or secondary surgical conver-
sion. Summarizing the available literature, outcomes are
encouraging, but seem to be predominantly determined by age
and co-morbidities [22, 26, 58].
TEVAR for TAD
Measures of outcome are identical to those of TAA. However, add-
itional information needs to encompass the fate of the distal aorta
involved in the dissection. The closure rate of the primary entry
tear and thrombosis of the false lumen of the stented segment of
the thoracic aorta is high in most series, but needs to be reported
in the long term [54]. It seems reasonable to accept continued per-
fusion of the false lumen in the abdomen distal from the stent-
graft site as long as aortic dilatation does not occur [59, 60].
EVALUATION OF RESULTS
Follow-up after TEVAR
Lifelong clinical and morphological surveillance is mandatory after
TEVAR as late treatment failure may develop even years after the
initial treatment [61]. Currently CTA is recommended prior to dis-
charge. Further follow-ups at 6 and 12 months is based on CTA,
thereafter MRI/CTA in addition to annual clinical follow-up should
be implemented. The imaging algorithm in case of detectable
endoleaks cannot be generalized and remains according to the
individual discretion of the treating physician.
PENDING QUESTIONS
Malperfusion
TEVAR has proved to be the modality of choice in the treatment
of malperfusion from dynamic true lumen compression.
Additional branch vessel stenting may be necessary in order to
resolve malperfusion related to static obstruction (false lumen
thrombosis). Interventional or surgical fenestration of the dissect-
ing membrane is not considered as ﬁrst line therapy [28]. So far,
the value of extending the stented aortic segment into the
abdominal aorta for persisting malperfusion after TEVAR by
implantation of additional uncovered stents distally (PETTICOAT
concept) requires further data collection and evaluation [62].
Endoleaks
The majority of endoleaks can be avoided by careful selection
particularly with regard to important morphological details such
as the length of the landing zone, use of multiple stents, length
of overlapping segments as well as severe angulation and
massive aortic calciﬁcation (porcelain aorta) [61].
TEVAR induced neurologic injury: brain
Brain injury after TEVAR is a major complication and most often
associated with the underlying pathology, excessive device
manipulation within the arch or intended or inadvertent over-
stenting of one or more of the great vessels. Further reduction in
the stroke rate will be feasible by aggressively maintaining ante-
grade cerebral perfusion through prior vascular transposition
[23]. Overstenting of the left subclavian artery is permissible in
the emergency setting (e.g. traumatic aortic injury), but is inad-
visable in elective cases due to a heightened risk of stroke and
spinal cord injury. Therefore, detailed information on cerebral
blood supply is required in elective situations [63, 64].
TEVAR induced neurologic injury: spinal cord
Spinal cord injury can occur immediately after TEVAR or be
delayed, requiring clinical and neurological surveillance. The risk
may be increased with extended lengths of the covered thoracic
aortic segments [65]. Recent reports underline the importance of
maintaining collateral blood supply via the left subclavian artery,
lumbar arteries as well as hypogastric arteries. Special attention
has to be paid to patients with previous treatment of AAA and
intended coverage of subclavian artery by TEVAR. In such cases
pre-deployment subclavian transposition would appear manda-
tory. In high-risk patients, preventive cerebrospinal ﬂuid (CSF)
drainage, which has proven efﬁcacy in spinal cord protection
during open thoraco-abdominal aneurysm surgery, is strongly
recommended [66].
Reversal of paraplegia can be achieved by the immediate initi-
ation of CSF drainage and pharmacological elevation of blood
pressure (>90 mmHg mean arterial pressure). Hypotensive epi-
sodes during the procedure should be avoided. Neurological
outcomes seem to be better with delayed occurrence of para-
plegia than with immediate paraplegia after TEVAR [67]. Finally, a
highly normal serum haemoglobin as well as precise attent to
oxygenation will serve to both, prevention and reversal.
Vascular complications
Vascular complications are rare when anatomy is respected.
Furthermore, the introduction of hydrophilic delivery sheaths
has substantially facilitated the introduction of devices in rela-
tively small access vessels. In calciﬁed vessels, open surgical
cut-down is preferred [46].
Retrograde aortic dissection
Retrograde aortic dissection may occur after TEVAR. However, it
is seen more frequently in acute aortic dissection and proce-
dures where the aortic arch or the ascending aorta is involved.
The role of bare proximal stents in retrograde type A dissection
remains undeﬁned [40, 41].
Aorto-oesophageal or aorto-bronchial ﬁstulation
Fistulation after TEVAR is rare and more frequently seen after
acute aortic syndromes than after elective procedures. The ﬁnal
common pathway in development may be local inﬂammation in
the posterior mediastinum [55, 56]. The treatment of choice is
radical oesophageal resection comparable to treatment of
oesophageal cancer.
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PERSPECTIVES
Progress of device development
Challenges in endograft design are the development of branched
endografts and of pathology-speciﬁc endografts [68–70].
However, the unique composition of the proximal thoracic aorta
as well as the associated mechanical properties have to be taken
into account and make this effort by far more complex than
initially expected. There is a need for reducing the dimension
(outer diameter) of the stent-graft devices, increasing the
conformability and trackability.
Pressure sensors
Despite the convincing concept, there are no data showing that
pressure sensors are superior to conventional imaging in order
to detect or prevent aortic-related adverse events [71].
Development of so-called ‘smart’ stents has to be expected.
Progress of imaging
Recently, there has been increasing interest in functional imaging
(assessment of ﬂow patterns, membrane dynamics, diameters
during the cardiac cycle, wall stress), which will help to improve
our understanding of aortic diseases and may be able to predict
future events [72]. This may be complemented by molecular
imaging of the aortic wall metabolism, which will provide import-
ant insights into the pathogenesis and healing process [10].
SYNOPSIS AND OUTLOOK
TEVAR has changed aortic medicine, enhancing the armamentar-
ium of the aortic specialist in treating acute and chronic thoracic
aortic disease. TEVAR offers a valid treatment option for the
elderly patients deemed at excessive risk for open surgery, but
also for ﬁt patients with suitable anatomies. Particularly, in
patients with traumatic aortic injury and acute complicated TAD,
TEVAR is considered the treatment of choice. A prerequisite is a
multidisciplinary team approach in centres with a dedicated
interest in aortic diseases. Therefore, the foundation of specia-
lized aortic centres providing the full range of diagnostic and
treatment options is strongly recommended.
Conﬂict of interest: none declared.
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